Coloplast A/S (CLPBY) Stock Forecast & Price Target

$10.65 +0.03 (+0.28%)

As of 04/17/2025 03:58 PM Eastern

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 3 Analyst Ratings

Sell
0

Hold
2

Buy
1

Based on 3 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a strong buy rating for CLPBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

CLPBY Analyst Ratings Over Time

Type	Current Forecast 4/20/24 to 4/20/25	1 Month Ago 3/21/24 to 3/21/25	3 Months Ago 1/21/24 to 1/20/25	1 Year Ago 4/21/23 to 4/20/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	N/A	N/A	N/A	N/A
Forecasted Upside	N/A	N/A	N/A	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coloplast A/S Stock vs. The Competition

Type	Coloplast A/S	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	21,675.79% Upside	26.48% Upside
News Sentiment Rating	Positive News See Recent CLPBY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating
3/3/2025	Royal Bank of Canada 4 of 5 stars	J. Reynolds-Clar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
1/28/2025	Sanford C. Bernstein 3 of 5 stars	L. Clive Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
12/11/2024	UBS Group 3 of 5 stars	G. Doyle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
11/18/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
9/5/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
7/10/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
6/1/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight
5/12/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:04 PM ET.

Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, April 13, 2025. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

Here are some ways that investors could benefit from investing in Coloplast A/S:

Coloplast A/S has shown a significant reduction in short interest, dropping by 16.3% in August 2024, indicating increased investor confidence and potentially positive market sentiment.
The company operates in a growing industry focused on intimate healthcare products, which is expected to expand as the global population ages and healthcare needs increase.
Coloplast A/S offers a diverse range of innovative products, including the latest SenSura Mio ostomy care solutions, which are designed for optimal discretion and fit, appealing to a broad customer base.
The current stock price of Coloplast A/S is reflective of its strong market position and product offerings, making it an attractive option for investors looking for stability in the healthcare sector.
With a robust portfolio that includes advanced wound care and continence care products, Coloplast A/S is well-positioned to capitalize on increasing demand for specialized healthcare solutions.

Coloplast A/S
Bear Case

Investors should be bearish about investing in Coloplast A/S for these reasons:

Despite the reduction in short interest, the overall market volatility can still pose risks to stock performance, particularly in the healthcare sector where regulatory changes can impact operations.
Coloplast A/S faces competition from other companies in the surgical appliances and supplies industry, which could affect its market share and pricing strategies.
The company's reliance on specific product segments, such as ostomy care and continence care, may expose it to risks if these markets experience downturns or shifts in consumer preferences.
Investors should consider the potential impact of economic downturns on healthcare spending, which could affect Coloplast A/S's sales and profitability.
While the company has a strong product lineup, any delays in product development or regulatory approvals could hinder growth and investor returns.

CLPBY Forecast - Frequently Asked Questions

: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last twelve months. There are currently 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CLPBY shares.
: According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Coloplast A/S's stock had 2 upgrades by analysts.
: Coloplast A/S has been rated by research analysts at Royal Bank of Canada, and Sanford C. Bernstein in the past 90 days.
: Analysts like Coloplast A/S less than other "medical" companies. The consensus rating score for Coloplast A/S is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CLPBY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (OTCMKTS:CLPBY) was last updated on 4/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coloplast A/S (CLPBY) Stock Forecast & Price Target